| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |